What can a UK aesthetics clinic legally advertise?

What actually decides whether an aesthetic product can be advertised?

It comes down to one legal fact: is the product a medicine, a medical device, or neither. Medicines that are prescription-only cannot be advertised to the public at all, under any wording. Medical devices and cosmetics generally can be, subject to the normal rules against misleading claims. Almost every advertising problem an aesthetics clinic runs into traces back to a product sitting on the wrong side of that line, or copy that puts it there by accident.

The rest of this page works through each row: what the law actually says, what MHRA and the ASA have done to clinics that got it wrong, and what you can safely write instead.

Is it true that many popular dermal fillers are prescription-only medicines because of their lidocaine content?

No, not as a blanket rule, though the underlying legal position is narrower and more interesting than a flat yes or no. Checked directly against MHRA's own published position, most lidocaine-containing fillers sold in the UK are marketed as medical devices, not medicines, because the lidocaine is treated as an ancillary ingredient added to reduce injection pain rather than the product's main action.

MHRA set out its own position in its response to the 2021 consultation on the future regulation of medical devices in the UK. Addressing exactly this question, it said: "the MHRA is not able to regulate them as a prescription only medicine (unless they do not have a medical purpose but contain a medicinal substance such as an anaesthetic), but rather as medical devices or, in some cases at the current time, general products" (GOV.UK, consultation outcome, Chapter 1). Read carefully, that sentence sets out three buckets, not two:

1. A filler used for a medical purpose is regulated as a medical device, in the normal way.
2. A filler with no medical purpose and no medicinal substance is not currently a medical device at all under the rules MHRA was describing, and falls into general product law.
3. A filler with no medical purpose that itself contains a medicinal substance, such as an anaesthetic like lidocaine, is the one circumstance in which MHRA says it can step in and treat the product as a medicinal product rather than a device.

That third bucket is the exception the owner's claim is reaching for, and it is real. But it is not what happens to the fillers a UK aesthetics clinic actually buys and injects. The branded ranges clinics commonly use with lidocaine, such as the Juvederm, Restylane and Radiesse lidocaine variants, are sold in the UK as Class III medical devices, according to the manufacturers' own product information, with the lidocaine present as an ancillary anaesthetic to reduce pain on injection, not as the product's therapeutic purpose. A Class III device is the highest device risk class, reserved for products implanted or injected into the body, which is why dermal fillers sit there rather than in a lower class. No UK marketing authorisation for a lidocaine-containing aesthetic dermal filler as a medicine was found while researching this page.

The practical answer for a clinic: treat your branded dermal fillers as medical devices, which is how MHRA and the manufacturers themselves classify them, and advertise them accordingly, meaning normal consumer-protection rules on not misleading rather than the POM ban. If you are ever offered, or asked to stock, a filler product with an unusual formulation you cannot find a device registration for, that is the point to check its status before advertising it, not after.

Why can't botulinum toxin be advertised at all, even truthfully?

Because the law does not distinguish between misleading and accurate advertising of a prescription-only medicine to the public. It bans the category outright. Botulinum toxin, under any brand (Botox, Bocouture, Azzalure, Dysport), is a prescription-only medicine, confirmed directly on its own product listing: the electronic Medicines Compendium classifies "BOTOX 100 Allergan Units" as a prescription only medicine. CAP Code rule 12.12 states plainly: "Prescription-only medicines or prescription-only medical treatments may not be advertised to the public." Nothing in that rule turns on whether the ad is true.

Behind the CAP rule sits the actual law. The Human Medicines Regulations 2012, regulation 284(1), states: "A person may not publish an advertisement that is likely to lead to the use of a prescription only medicine." This is Part 14 of the Regulations, the part covering advertising, and it applies whether the ad appears on Meta, on your own website, on a printed flyer, or on a physical sign outside the clinic.

The ASA's enforcement notice on advertising Botox and other botulinum toxin injections spells out how far this reaches in practice, and it is further than most clinics assume:

• Brand names and images are banned, including in hashtags such as #botox.
• Invented names where the obvious inference is Botox are banned, the notice's own examples being "Beautytox" and "Beautox".
• Indirect phrases that can only mean the medicine are "just as much of a problem" as naming it, the notice's example being "wrinkle relaxing injections".
• "Anti-wrinkle injections" shown with a price is treated as an ad for the medicine, because a price makes clear you are being sold the treatment, not just informed about the service.
• Wording naming a medical condition the toxin treats, such as "injections for excessive sweating", is also banned; use "treatments for excessive sweating" if you offer a non-POM option.
• Juxtaposing "anti-wrinkle injections and dermal fillers" implies the injections are also a POM, even where the filler reference is fine on its own.

What the notice does allow is promoting the service and the consultation itself. It states that wording such as "a consultation for the treatment of lines and wrinkles" may be acceptable, provided nothing directly or indirectly advertises the medicine. That is the gap almost every compliant aesthetics ad in the UK is built around: sell the appointment, never the drug.

Is a breach treated as a criminal matter, or just a marketing problem?

Criminal. This is the point clinic owners most often get wrong, and it is worth stating without softening it: breaching regulation 284 is a criminal offence under the Human Medicines Regulations 2012, not a matter the ASA resolves by asking you to take an ad down.

Regulation 303 sets the penalty. Breaching any provision in the relevant chapter, which includes regulation 284, is an offence: on summary conviction, a fine not exceeding the statutory maximum; on conviction on indictment, a fine, imprisonment for up to two years, or both. The advertising prosecution in the table below, Nadine Poole in Northern Ireland, was brought by the Department of Health's Medicines Regulatory Group under these Regulations. MHRA's own enforcement has focused on illegal supply, under the same penalty: "Anyone caught selling or supplying unlicensed botulinum toxin faces up to two years in prison and unlimited fines under the Human Medicines Regulations 2012." Since May 2023 its Criminal Enforcement Unit, with Border Force, has seized more than 4,700 vials of unlicensed botulinum toxin, almost all originating in South Korea.

The ASA's own process reflects the same split. Its enforcement notice says it uses monitoring technology to find non-compliant posts, and where an advertiser will not fix the problem voluntarily, it can refer the matter on to MHRA or to the advertiser's professional regulator, rather than treating the ASA's own sanctions as the end of the road. In other words, the ASA ruling is often the first step, not the last one, if a clinic keeps repeating the same breach.

What has actually happened to clinics and practitioners who got this wrong?

These are not hypothetical risks. The table below covers named, verified cases from the past three years, each on the regulator's or court reporting body's own page, and each illustrating a different way clinics have fallen foul of the rules above.

Two patterns run through all five. First, wording that names a price next to a treatment that is understood to be anti-wrinkle injections gets treated as advertising the medicine, whatever else is on the same page. Second, a clinic's own name, an influencer's post, and even a discount structure are all in scope, not only the obvious "buy Botox here" ad. The LIFT Aesthetics case in particular shows that a celebrity's own Instagram Stories, reposted by the clinic, carry the same liability as an ad the clinic wrote itself.

What is Botox actually licensed for, and does that matter for advertising?

Botox's UK licence for cosmetic use covers four facial-line indications, not one. Checked directly against the current Summary of Product Characteristics for BOTOX 100 Allergan Units on the electronic Medicines Compendium, the cosmetic indications are the temporary improvement in the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows), lateral canthal lines (crow's feet), forehead lines, and platysma prominence. That is glabellar lines (between the eyebrows), crow's feet, forehead lines and platysma prominence (neck banding), four distinct licensed cosmetic uses, not glabellar lines alone. The same product also holds entirely separate medical licences with no bearing on aesthetics advertising, including symptomatic relief of blepharospasm, hemifacial spasm and cervical dystonia, prophylaxis of chronic migraine, management of certain bladder dysfunctions, and treatment of severe hyperhidrosis of the axillae.

The two other brands most UK clinics use for cosmetic work have narrower, though overlapping, licences. Bocouture's SmPC covers "upper facial lines in adults below 65 years... glabellar frown lines... and/or... crow's feet lines... and/or... horizontal forehead lines". Azzalure's SmPC covers "glabellar lines... seen at maximum frown and/or lateral canthal lines (crow's feet lines) seen at maximum smile in adult patients under 65 years." Put together as a table:

Why this matters, given that none of it can be advertised anyway: off-label use itself is legal for a prescriber to offer in a one-to-one clinical setting, using their own professional judgement, but it cannot be advertised, and neither can the licensed use. The distinction matters for what a practitioner tells a patient in consultation and what is recorded in consent paperwork, not for what goes in an ad. A clinic that describes an unlicensed use as though it were standard, in marketing material aimed at patients rather than in the consultation room, adds a second problem on top of the POM ban: a misleading claim under the general CAP Code rules on substantiation, separate from rule 12.12.

Can a clinic advertise to under-18s, or treat them?

No, on both counts, and these are two separate rules with two separate dates. Advertising: since 25 May 2022, ASA rules require that cosmetic intervention advertising must not be directed at under-18s through the choice of media or context. That is a targeting rule, covering where and how you advertise, not just what age you claim to want.

Treatment itself is a separate, stricter rule under the Botulinum Toxin and Cosmetic Fillers (Children) Act 2021. Sections 1 to 4 of the Act, the offence and enforcement provisions, came into force on 1 October 2021. Section 1 states: "It is an offence for a person to administer, in England, to another person ('A')... botulinum toxin, or... a subcutaneous, submucous or intradermal injection of a filler for a cosmetic purpose, where A is under the age of 18," and a person convicted is liable on summary conviction to a fine. The Act carries a defence for a registered medical practitioner, or a regulated health professional acting on a doctor's direction, so it targets non-medical, unsupervised administration rather than clinically overseen prescribing decisions. For a clinic, the practical rule is the same either way: verify age before booking, and keep your ad targeting set to 18 and over on every platform you use, not just the ones with an automatic age gate.

Is a licensing scheme for cosmetic procedures coming in England?

Yes, but it is not law yet, and treating it as settled would be a mistake. The Health and Care Act 2022, section 180, already gives the Secretary of State the power to make regulations "prohibiting an individual in England from carrying out specified cosmetic procedures in the course of business, unless the person has a personal licence," and separately requiring a premises licence to use premises for those procedures. That power has existed since 2022; what has not yet happened is the government actually using it.

On 6 August 2025, the Department of Health and Social Care announced the shape the scheme will take, following a 2023 consultation that closed on 28 October 2023. The announcement sets out two groups: the highest-risk procedures, DHSC's own example being non-surgical Brazilian butt lifts, restricted to qualified healthcare workers in providers registered with the CQC; and lower-risk treatments, explicitly including "Botox, lip fillers and facial dermal fillers", brought under a new local authority licensing system, with practitioners required to meet safety, training and insurance standards. When this page was checked on 29 September 2026, we found no regulations bringing the scheme into force on legislation.gov.uk or GOV.UK. It remains a stated policy direction, confirmed by government, sitting on top of a power that already exists in law, rather than a live licensing requirement a clinic must comply with today.

Scotland is further along. A draft Civic Government (Scotland) Act 1982 (Licensing of Non-surgical Procedures) Order 2026 has been laid before the Scottish Parliament, and the draft text says the activity "is to be licensed from 6 September 2027", with transitional provision for earlier applications. It is a draft, and legislation.gov.uk shows it has since been replaced by a newer draft, so treat the date as indicative. A clinic operating only in England is not covered by it.

This section describes government policy and legislative powers as they stood when this page was last checked (29 September 2026). Licensing timelines in this area have moved before; confirm the current position on GOV.UK before relying on it for a compliance decision.

What does compliant ad wording actually look like next to non-compliant wording?

The pattern behind every enforcement case above is the same: describe the appointment and the practitioner, not the medicine and not a promised result. The table below sets out the pattern using only wording the regulators themselves have already used in published rulings and guidance, not invented ad copy.

The same standard applies whether the content is a paid ad, an organic post on the clinic's own page, a landing page, or a practitioner's personal account. The ASA's enforcement notice covers "paid ads, organic posts on your own or others' pages, and influencer marketing" as a single scope; the only carve-out is advertising aimed solely at healthcare professionals. A clinic name itself counts too, as Dr Bunny Aesthetics shows: if your business name implies a qualification, a treatment, or a claim you cannot substantiate, the name is the ad.

How does PatientFlow handle this?

PatientFlow builds every campaign around the consultation, never a named medicine, a price against an anti-wrinkle treatment, or a before-and-after claim for a POM. Ads run from the clinic's own Meta ad account, so the compliance history sits with an account the clinic owns, not one it shares with an agency's other clients. For Dr Motox that approach produced 160 deposit-paid bookings in four months at £36 each. Every enquiry is then answered on WhatsApp in under 60 seconds and qualified on treatment, suitability, budget and timing before a deposit confirms the consultation. For the platform side of compliance, including Meta's own Health and Wellness and Personal Attributes policies, see why Meta rejects aesthetics clinic ads, and for the wider marketing picture see the best way to market an aesthetics clinic in the UK.

A pre-flight checklist before you advertise anything aesthetic

1. Check whether the product is a medicine (like botulinum toxin) or a device (like a branded dermal filler). If you are not sure, treat it as a medicine until you have confirmed otherwise, since the penalty for getting it wrong is criminal, not just a rejected ad.
2. Never name botulinum toxin, a brand of it, or an invented stand-in name, anywhere in an ad, an image, a hashtag, a landing page, or your business name.
3. Never show a price next to "anti-wrinkle injections", "cosmetic injections", or any phrase a patient would read as meaning Botox.
4. Advertise the consultation and the practitioner instead. Wording such as "a consultation for the treatment of lines and wrinkles" is the regulator's own suggested pattern.
5. If an influencer, celebrity or member of staff appears being injected or discussing the treatment, label the post clearly as an ad and keep any discussion of a medicine's benefits out of it.
6. Set every cosmetic ad to a minimum age of 18, and keep placements away from under-18-skewed audiences and content.
7. If your clinic or practitioner name implies a medical qualification, hold the evidence for it, or change the name.
8. Treat dermal fillers as the product you can advertise, but never let filler copy sit next to anti-wrinkle wording in a way that implies both are on offer together.
9. Check GOV.UK directly before advising on England's cosmetic procedures licensing scheme; as of the date this page was checked it is announced policy, not yet in force.

This is general guidance on UK advertising and medicines law, not legal advice. Rules, rulings and licensing timelines in this area change; check the CAP Code, the Human Medicines Regulations, and GOV.UK directly before relying on any point here for a specific ad or a specific product.